Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Eli Lilly to supply Canada 26,000 doses of bamlanivimab for $32.5M » 12:56
11/24/20
11/24
12:56
11/24/20
12:56
LLY

Eli Lilly

$144.96 /

+1.53 (+1.07%)

Eli Lilly Canada…

Eli Lilly Canada announced that Lilly and the Government of Canada have signed an agreement for the supply of bamlanivimab to Canada. Lilly will supply Canada with an initial quantity of 26,000 doses of bamlanivimab over the three-month period between December 2020 and February 2021, for $32.5M. Additional doses will be supplied to Canada on a monthly basis according to the medical need in Canada and the availability of supply. The Government of Canada will be working with provincial and territorial partners to equitably allocate supply, while recognizing the need for flexibility based on COVID-19 activity across the country. Bamlanivimab received authorization for its use as a treatment of adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization.

ShowHide Related Items >><<
LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

LLY Eli Lilly
$144.96 /

+1.53 (+1.07%)

Yesterday
Periodicals
EU seeks easier access to generic medicines, Reuters says » 14:48
11/23/20
11/23
14:48
11/23/20
14:48
JNJ

Johnson & Johnson

$143.20 /

-1.13 (-0.78%)

, LLY

Eli Lilly

$142.01 /

-3.63 (-2.49%)

, MRK

Merck

$79.63 /

-0.81 (-1.01%)

, PFE

Pfizer

$36.32 /

-0.38 (-1.04%)

, SNY

Sanofi

$49.53 /

-0.93 (-1.84%)

, AZN

AstraZeneca

$54.26 /

-1.03 (-1.86%)

, GSK

GlaxoSmithKline

$36.54 /

-0.49 (-1.32%)

, NVS

Novartis

$87.00 /

-0.505 (-0.58%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.26 /

-0.365 (-0.59%)

The European Commission…

The European Commission is seeking to make it easier for patients to gain access to cheaper, generic medicines, in a move that could affect the revenues of large pharmaceutical companies, Reuters' Francesco Guarascio reports, citing a draft EU document. The document explains the EU executive's strategy for the sector in a document due to be published later this week, with the goal of making drugs more affordable and preventing the serious shortages seen in the first phase of the coronavirus crisis earlier this year, the author says. "The Commission will consider targeted policies that support greater generic and biosimilar competition," the document says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$49.53 /

-0.93 (-1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.32 /

-0.38 (-1.04%)

NVS Novartis
$87.00 /

-0.505 (-0.58%)

MRK Merck
$79.63 /

-0.81 (-1.01%)

LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

11/23/20 SVB Leerink
AstraZeneca vaccine 'will never be licensed in the U.S.,' says SVB Leerink
11/12/20 Chardan
Immunovant price target raised to $60 from $45 at Chardan
11/10/20 Piper Sandler
Aligos Therapeutics initiated with an Overweight at Piper Sandler
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
MRK Merck
$79.63 /

-0.81 (-1.01%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
PFE Pfizer
$36.32 /

-0.38 (-1.04%)

11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Goldman Sachs
Pfizer reinstated with a Neutral at Goldman Sachs
11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
SNY Sanofi
$49.53 /

-0.93 (-1.84%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

11/23/20 Morgan Stanley
AstraZeneca price target raised to 9,400 GBp from 9,000 GBp at Morgan Stanley
11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
NVS Novartis
$87.00 /

-0.505 (-0.58%)

11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
SNY Sanofi
$49.53 /

-0.93 (-1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.32 /

-0.38 (-1.04%)

NVS Novartis
$87.00 /

-0.505 (-0.58%)

MRK Merck
$79.63 /

-0.81 (-1.01%)

LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

SNY Sanofi
$49.53 /

-0.93 (-1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.32 /

-0.38 (-1.04%)

NVS Novartis
$87.00 /

-0.505 (-0.58%)

MRK Merck
$79.63 /

-0.81 (-1.01%)

LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

SNY Sanofi
$49.53 /

-0.93 (-1.84%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.32 /

-0.38 (-1.04%)

NVS Novartis
$87.00 /

-0.505 (-0.58%)

MRK Merck
$79.63 /

-0.81 (-1.01%)

LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

PFE Pfizer
$36.32 /

-0.38 (-1.04%)

MRK Merck
$79.63 /

-0.81 (-1.01%)

LLY Eli Lilly
$142.01 /

-3.63 (-2.49%)

JNJ Johnson & Johnson
$143.20 /

-1.13 (-0.78%)

GSK GlaxoSmithKline
$36.54 /

-0.49 (-1.32%)

BMY Bristol-Myers
$61.26 /

-0.365 (-0.59%)

AZN AstraZeneca
$54.26 /

-1.03 (-1.86%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 10:25
11/23/20
11/23
10:25
11/23/20
10:25
GILD

Gilead

$59.85 /

-0.25 (-0.42%)

, LLY

Eli Lilly

$143.43 /

-2.21 (-1.52%)

, REGN

Regeneron

$521.45 /

+1.88 (+0.36%)

, HGEN

Humanigen

$8.72 /

-0.15 (-1.69%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

11/23/20 Piper Sandler
Regeneron Covid cocktail could be meaningful to earnings, says Piper Sandler
11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

REGN Regeneron
$521.45 /

+1.88 (+0.36%)

LLY Eli Lilly
$143.43 /

-2.21 (-1.52%)

HGEN Humanigen
$8.72 /

-0.15 (-1.69%)

GILD Gilead
$59.85 /

-0.25 (-0.42%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 04:55
11/23/20
11/23
04:55
11/23/20
04:55
GILD

Gilead

$60.10 /

-0.53 (-0.87%)

, LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

, REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, HGEN

Humanigen

$8.88 /

+0.61 (+7.38%)

Biopharmaceuticals…

Biopharmaceuticals Analysts Chen & Kim and Biotechnology Analyst Young, along with Gerald Pier, PhD, Professor of Medicine, Microbiology & Immunology at Harvard Medical School, discuss Monoclonal Antibodies to treat COVID-19 on an Analyst/Industry conference call to be held on November 23 at 11 am.

ShowHide Related Items >><<
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

11/20/20 Raymond James
Use of Gilead's remdesivir likely to skew to U.S. into Q1, says Raymond James
11/03/20
Fly Intel: Top five analyst initiations
11/03/20 Morgan Stanley
Gilead resumed with an Equal Weight at Morgan Stanley
10/29/20 BMO Capital
Gilead price target lowered to $64 from $74 at BMO Capital
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

11/06/20 H.C. Wainwright
Humanigen price target raised to $34 from $31 at H.C. Wainwright
10/21/20
Fly Intel: Top five analyst initiations
10/21/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
10/20/20 Cantor Fitzgerald
Humanigen initiated with an Overweight at Cantor Fitzgerald
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

  • 18
    Sep
  • 27
    May
REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

HGEN Humanigen
$8.88 /

+0.61 (+7.38%)

GILD Gilead
$60.10 /

-0.53 (-0.87%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:03
11/21/20
11/21
09:03
11/21/20
09:03
REGN

Regeneron

$519.36 /

+4.81 (+0.93%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, IFNNY

Infineon

$0.00 /

+ (+0.00%)

, AZN

AstraZeneca

$55.29 /

+1.27 (+2.35%)

, BMY

Bristol-Myers

$61.62 /

-0.47 (-0.76%)

, LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

, GSK

GlaxoSmithKline

$37.03 /

-0.11 (-0.30%)

, JNJ

Johnson & Johnson

$146.33 /

-0.76 (-0.52%)

, MRK

Merck

$80.46 /

+0.04 (+0.05%)

, NVS

Novartis

$87.51 /

+0.285 (+0.33%)

, PFE

Pfizer

$36.70 /

+0.51 (+1.41%)

, SNY

Sanofi

$50.47 /

-0.34 (-0.67%)

Catch up on the top…

ShowHide Related Items >><<
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
11/06/20 Truist
Regeneron price target raised to $770 from $750 at Truist
11/05/20 Piper Sandler
Regeneron shares will continue moving higher, says Piper Sandler
RHHBY Roche
$0.00 /

+ (+0.00%)

10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
IFNNY Infineon
$0.00 /

+ (+0.00%)

11/10/20 Morgan Stanley
Infineon price target raised to EUR 30.50 from EUR 30 at Morgan Stanley
11/10/20 Deutsche Bank
Infineon price target raised to EUR 33 from EUR 27 at Deutsche Bank
11/05/20 Credit Suisse
Infineon price target raised to EUR 22.50 from EUR 19.20 at Credit Suisse
10/26/20 Morgan Stanley
Infineon price target raised to EUR 30 from EUR 25 at Morgan Stanley
AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

11/12/20 Chardan
Immunovant price target raised to $60 from $45 at Chardan
11/10/20 Piper Sandler
Aligos Therapeutics initiated with an Overweight at Piper Sandler
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
10/14/20 Credit Suisse
Johnson & Johnson price target raised to $168 from $163 at Credit Suisse
MRK Merck
$80.46 /

+0.04 (+0.05%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
NVS Novartis
$87.51 /

+0.285 (+0.33%)

11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
PFE Pfizer
$36.70 /

+0.51 (+1.41%)

11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Goldman Sachs
Pfizer reinstated with a Neutral at Goldman Sachs
11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

  • 27
    May
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

IFNNY Infineon
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

REGN Regeneron
$519.36 /

+4.81 (+0.93%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

Friday
Hot Stocks
Trump to sign orders in effort to cut prescription drug prices » 16:52
11/20/20
11/20
16:52
11/20/20
16:52
JNJ

Johnson & Johnson

$146.33 /

-0.76 (-0.52%)

, LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

, MRK

Merck

$80.46 /

+0.04 (+0.05%)

, PFE

Pfizer

$36.70 /

+0.51 (+1.41%)

, SNY

Sanofi

$50.47 /

-0.34 (-0.67%)

, AZN

AstraZeneca

$55.29 /

+1.27 (+2.35%)

, GSK

GlaxoSmithKline

$37.03 /

-0.11 (-0.30%)

, NVS

Novartis

$87.51 /

+0.285 (+0.33%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.62 /

-0.47 (-0.76%)

U.S. President Donald…

U.S. President Donald Trump announced that his administration is issuing two rules to "very dramatically" lower the price of prescription drugs for the American people, especially for seniors. The first action will be to prevent middlemen from "ripping off" Medicare patients with high prescription prices. The second action the administration is finalizing will " transform the way the U.S. government pays for drugs to end global freeloading on the backs of American citizens and American patients," the president said. "Medicare will now look at the price that other developed nations pay for their drugs," Trump added. "And instead of paying the highest price on that list - and we are substantially higher than any other country in the world - we will pay the lowest price. In other words, we take the lowest price, and we match whatever the lowest price is, leading to colossal savings for all Americans. And we're talking about savings of 50, 60, 70 percent, 80 percent - different drugs, different prices." Trump also announced that the White House is ending the Unapproved Drugs Initiative program to put a stop to the "unfair" practice of allowing drug companies to identify certain older generic drugs that have been widely available for decades and exploit a misguided program called "Unapproved Drugs Initiative" to obtain market exclusivity on these medicines. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link

ShowHide Related Items >><<
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

11/12/20 Chardan
Immunovant price target raised to $60 from $45 at Chardan
11/10/20 Piper Sandler
Aligos Therapeutics initiated with an Overweight at Piper Sandler
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
10/14/20 Credit Suisse
Johnson & Johnson price target raised to $168 from $163 at Credit Suisse
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
MRK Merck
$80.46 /

+0.04 (+0.05%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
PFE Pfizer
$36.70 /

+0.51 (+1.41%)

11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Goldman Sachs
Pfizer reinstated with a Neutral at Goldman Sachs
11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
NVS Novartis
$87.51 /

+0.285 (+0.33%)

11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

SNY Sanofi
$50.47 /

-0.34 (-0.67%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

NVS Novartis
$87.51 /

+0.285 (+0.33%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

PFE Pfizer
$36.70 /

+0.51 (+1.41%)

MRK Merck
$80.46 /

+0.04 (+0.05%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

JNJ Johnson & Johnson
$146.33 /

-0.76 (-0.52%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.62 /

-0.47 (-0.76%)

AZN AstraZeneca
$55.29 /

+1.27 (+2.35%)

Hot Stocks
Eli Lilly's LY-CoV555 gets interim authorization as a COVID treatment in Canada » 16:35
11/20/20
11/20
16:35
11/20/20
16:35
LLY

Eli Lilly

$145.62 /

+2.16 (+1.51%)

The company states:…

The company states: "Health Canada granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of bamlanivimab, or LY-CoV555, as a treatment for adults and pediatric patients 12 years of age or older with mild to moderate COVID-19 who weigh at least 40 kg and are at high risk of progressing to severe COVID-19 illness and/or hospitalization, Eli Lilly announced. This authorization, the second authorization around the world for bamlanivimab, is based on data from BLAZE-1, a randomized, double-blind placebo-controlled phase 2 study in patients with recently diagnosed, mild to moderate COVID-19. In BLAZE-1, patients treated with bamlanivimab showed reduced viral load and rates of symptoms and hospitalization. In BLAZE-1, frequency and types of adverse events were similar between bamlanivimab and placebo, with the majority being mild to moderate in severity. Infusion reactions and other allergic hypersensitivity events have been reported. Lilly has a robust, global supply chain in place and began large-scale manufacturing of bamlanivimab at risk earlier this year. Lilly anticipates manufacturing up to one million doses of bamlanivimab 700 mg by the end of 2020, for use around the world through early next year. On November 9th, the FDA granted Emergency Use Authorization for bamlanivimab 700 mg. In the U.S., bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older who weigh at least 40 kg with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. Lilly is in discussions with global regulators to make bamlanivimab available around the world. The company is focused on areas with the highest disease burden and pursuing authorization in countries such as India, Brazil, Russia and across Europe. Global allocation will be made based on Lilly's guiding principles that aim to ensure access for patients with high unmet need, no matter where they live."

ShowHide Related Items >><<
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

11/20/20 Stifel
Precision BioSciences price target raised to $22 from $21 at Stifel
11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

LLY Eli Lilly
$145.62 /

+2.16 (+1.51%)

Recommendations
Precision BioSciences price target raised to $22 from $21 at Stifel » 15:49
11/20/20
11/20
15:49
11/20/20
15:49
DTIL

Precision BioSciences

$10.75 /

+1.12 (+11.63%)

, LLY

Eli Lilly

$144.88 /

+1.42 (+0.99%)

Stifel analyst Benjamin…

Stifel analyst Benjamin Burnett raised the firm's price target on Precision BioSciences (DTIL) to $22 from $21 and keeps a Buy rating on the shares following the company announcing a genome editing collaboration with Eli Lilly (LLY). The analyst believes this "brings outside validation for what [he thinks] is an often overlooked aspect of the business," and also comes with an upfront cash infusion of $135M, as well as $420M in potential milestones.

ShowHide Related Items >><<
LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

DTIL Precision BioSciences
$10.75 /

+1.12 (+11.63%)

DTIL Precision BioSciences
$10.75 /

+1.12 (+11.63%)

10/21/20 Stifel
Crispr Therapeutics price target raised to $93 from $75 at Stifel
07/27/20 BTIG
Precision BioSciences assumed with a Buy at BTIG
05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

DTIL Precision BioSciences
$10.75 /

+1.12 (+11.63%)

LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

DTIL Precision BioSciences
$10.75 /

+1.12 (+11.63%)

LLY Eli Lilly
$144.88 /

+1.42 (+0.99%)

Hot Stocks
Trump announces new actions intended to limit drug prices » 14:41
11/20/20
11/20
14:41
11/20/20
14:41
JNJ

Johnson & Johnson

$146.76 /

-0.33 (-0.22%)

, LLY

Eli Lilly

$145.42 /

+1.96 (+1.37%)

, MRK

Merck

$80.68 /

+0.26 (+0.32%)

, PFE

Pfizer

$36.85 /

+0.66 (+1.82%)

, SNY

Sanofi

$50.55 /

-0.26 (-0.51%)

, AZN

AstraZeneca

$55.09 /

+1.07 (+1.98%)

, GSK

GlaxoSmithKline

$37.03 /

-0.11 (-0.30%)

, NVS

Novartis

$87.33 /

+0.11 (+0.13%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$61.96 /

-0.135 (-0.22%)

President Donald Trump is…

President Donald Trump is discussing two new executive actions aimed at limiting drug prices in a press conference from the White House. Publicly traded drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$50.55 /

-0.26 (-0.51%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.85 /

+0.66 (+1.82%)

NVS Novartis
$87.33 /

+0.11 (+0.13%)

MRK Merck
$80.68 /

+0.26 (+0.32%)

LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

11/12/20 Chardan
Immunovant price target raised to $60 from $45 at Chardan
11/10/20 Piper Sandler
Aligos Therapeutics initiated with an Overweight at Piper Sandler
10/26/20 RBC Capital
Morphic Holding initiated with an Outperform at RBC Capital
10/14/20 Credit Suisse
Johnson & Johnson price target raised to $168 from $163 at Credit Suisse
LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
MRK Merck
$80.68 /

+0.26 (+0.32%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
PFE Pfizer
$36.85 /

+0.66 (+1.82%)

11/19/20
Fly Intel: Top five analyst initiations
11/19/20 Goldman Sachs
Pfizer reinstated with a Neutral at Goldman Sachs
11/17/20 Benchmark
Inovio on 'top-10 vaccine contenders list,' says Benchmark
11/17/20 Maxim
Co-Diagnostics price target lowered to $20 from $30 at Maxim
SNY Sanofi
$50.55 /

-0.26 (-0.51%)

11/03/20 Morgan Stanley
Sanofi price target lowered to EUR 105 from EUR 107 at Morgan Stanley
10/30/20 JPMorgan
Sanofi price target lowered to EUR 100 from EUR 106 at JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
NVS Novartis
$87.33 /

+0.11 (+0.13%)

11/10/20 JPMorgan
Novartis price target raised to CHF 85 from CHF 82 at JPMorgan
10/26/20 JMP Securities
Kura Oncology price target raised to $33 from $22 at JMP Securities
09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

11/17/20 Mizuho
Bristol-Myers Squibb CVR price target lowered to $3.34 from $6.17 at Mizuho
11/16/20 Societe Generale
Bristol-Myers upgraded to Buy from Hold at Societe Generale
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
SNY Sanofi
$50.55 /

-0.26 (-0.51%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.85 /

+0.66 (+1.82%)

NVS Novartis
$87.33 /

+0.11 (+0.13%)

MRK Merck
$80.68 /

+0.26 (+0.32%)

LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

SNY Sanofi
$50.55 /

-0.26 (-0.51%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.85 /

+0.66 (+1.82%)

NVS Novartis
$87.33 /

+0.11 (+0.13%)

MRK Merck
$80.68 /

+0.26 (+0.32%)

LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

SNY Sanofi
$50.55 /

-0.26 (-0.51%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$36.85 /

+0.66 (+1.82%)

NVS Novartis
$87.33 /

+0.11 (+0.13%)

MRK Merck
$80.68 /

+0.26 (+0.32%)

LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

PFE Pfizer
$36.85 /

+0.66 (+1.82%)

MRK Merck
$80.68 /

+0.26 (+0.32%)

LLY Eli Lilly
$145.42 /

+1.96 (+1.37%)

JNJ Johnson & Johnson
$146.76 /

-0.33 (-0.22%)

GSK GlaxoSmithKline
$37.03 /

-0.11 (-0.30%)

BMY Bristol-Myers
$61.96 /

-0.135 (-0.22%)

AZN AstraZeneca
$55.09 /

+1.07 (+1.98%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
11/20/20
11/20
08:55
11/20/20
08:55
DTIL

Precision BioSciences

$9.68 /

+0.21 (+2.22%)

, LGVW

Longview Acquisition Corp.

$9.86 /

+0.07 (+0.72%)

, FL

Foot Locker

$41.36 /

+1.35 (+3.37%)

, BKE

The Buckle

$28.81 /

+1.125 (+4.06%)

, HIBB

Hibbett Sports

$42.14 /

+1.86 (+4.62%)

, HHR

HeadHunter

$25.33 /

-0.515 (-1.99%)

, WSM

Williams-Sonoma

$101.32 /

+4.245 (+4.37%)

, DXLG

Destination XL

$0.38 /

+0.0258 (+7.30%)

, GSX

GSX Techedu

$71.50 /

+3.53 (+5.19%)

, WDAY

Workday

$230.93 /

+7.31 (+3.27%)

, AVRO

Avrobio

$16.95 /

-0.365 (-2.11%)

, LLY

Eli Lilly

$143.46 /

+3.31 (+2.36%)

, BFLY

Butterfly Network

$0.00 /

+ (+0.00%)

Check out this morning's…

ShowHide Related Items >><<
WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

WDAY Workday
$230.93 /

+7.31 (+3.27%)

LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

LGVW Longview Acquisition Corp.
$9.86 /

+0.07 (+0.72%)

HIBB Hibbett Sports
$42.14 /

+1.86 (+4.62%)

HHR HeadHunter
$25.33 /

-0.515 (-1.99%)

GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

FL Foot Locker
$41.36 /

+1.35 (+3.37%)

DXLG Destination XL
$0.38 /

+0.0258 (+7.30%)

DTIL Precision BioSciences
$9.68 /

+0.21 (+2.22%)

BKE The Buckle
$28.81 /

+1.125 (+4.06%)

AVRO Avrobio
$16.95 /

-0.365 (-2.11%)

DTIL Precision BioSciences
$9.68 /

+0.21 (+2.22%)

10/21/20 Stifel
Crispr Therapeutics price target raised to $93 from $75 at Stifel
07/27/20 BTIG
Precision BioSciences assumed with a Buy at BTIG
05/18/20 H.C. Wainwright
Precision BioSciences could have 'significant upside,' says H.C. Wainwright
04/02/20 Goldman Sachs
Precision BioSciences downgraded to Neutral from Buy at Goldman Sachs
LGVW Longview Acquisition Corp.
$9.86 /

+0.07 (+0.72%)

FL Foot Locker
$41.36 /

+1.35 (+3.37%)

11/18/20 B. Riley Securities
Foot Locker price target raised to $36 from $30 at B. Riley Securities
11/18/20 Pivotal Research
Foot Locker price target raised to $46 from $39 at Pivotal Research
11/17/20 Wedbush
Foot Locker price target raised to $44 from $37 at Wedbush
11/16/20 Raymond James
Foot Locker price target raised to $50 from $35 at Raymond James
BKE The Buckle
$28.81 /

+1.125 (+4.06%)

HIBB Hibbett Sports
$42.14 /

+1.86 (+4.62%)

10/02/20 Susquehanna
Hibbett Sports price target raised to $50 from $40 at Susquehanna
08/28/20 Baird
Hibbett Sports price target raised to $35 from $28 at Baird
08/11/20 Barclays
Dick's Sporting price target raised to $51 from $45 at Barclays
07/21/20 Baird
Hibbett Sports price target raised to $28 from $22 at Baird
HHR HeadHunter
$25.33 /

-0.515 (-1.99%)

06/23/20 BCS Global
HeadHunter downgraded to Sell from Hold at BCS Global
03/11/20 JPMorgan
HeadHunter price target lowered to $15 from $16 at JPMorgan
WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

11/20/20 Loop Capital
Williams-Sonoma price target raised to $110 from $100 at Loop Capital
11/20/20 Wedbush
Williams-Sonoma price target raised to $130 from $115 at Wedbush
11/20/20 Barclays
Williams-Sonoma price target raised to $144 from $112 at Barclays
11/13/20 JPMorgan
Williams-Sonoma price target lowered to $80 from $95 at JPMorgan
DXLG Destination XL
$0.38 /

+0.0258 (+7.30%)

03/20/20 Lake Street
Destination XL price target lowered to $3 from $4 at Lake Street
GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

10/26/20 Barclays
GSX Techedu price target lowered to $66 from $77 at Barclays
10/22/20
Fly Intel: Top five analyst downgrades
10/22/20 Nomura
Nomura downgrades GSX Techedu to Reduce, cuts target to 'Street-low' $38
10/22/20 Nomura
GSX Techedu downgraded to Reduce from Neutral at Nomura
WDAY Workday
$230.93 /

+7.31 (+3.27%)

11/20/20 Loop Capital
Workday price target raised to $180 from $170 at Loop Capital
11/20/20 Canaccord
Workday weakness following earnings should be bought, says Canaccord
11/20/20 BMO Capital
Workday price target lowered to $260 from $265 at BMO Capital
11/20/20 Credit Suisse
Workday price target raised to $230 from $215 at Credit Suisse
AVRO Avrobio
$16.95 /

-0.365 (-2.11%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

11/17/20 Mizuho
Eli Lilly price target lowered to $156 from $164 at Mizuho
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform, $150 price target at Bernstein
11/10/20 Bernstein
Eli Lilly initiated with a Market Perform at Bernstein
11/10/20 SVB Leerink
Regeneron price target lowered to $643 from $653 at SVB Leerink
BFLY Butterfly Network
$0.00 /

+ (+0.00%)

WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

WDAY Workday
$230.93 /

+7.31 (+3.27%)

LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

HIBB Hibbett Sports
$42.14 /

+1.86 (+4.62%)

HHR HeadHunter
$25.33 /

-0.515 (-1.99%)

GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

FL Foot Locker
$41.36 /

+1.35 (+3.37%)

DXLG Destination XL
$0.38 /

+0.0258 (+7.30%)

DTIL Precision BioSciences
$9.68 /

+0.21 (+2.22%)

BKE The Buckle
$28.81 /

+1.125 (+4.06%)

AVRO Avrobio
$16.95 /

-0.365 (-2.11%)

  • 20
    Nov
  • 16
    Jul
  • 13
    Feb
  • 21
    Nov
WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

HHR HeadHunter
$25.33 /

-0.515 (-1.99%)

GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

DXLG Destination XL
$0.38 /

+0.0258 (+7.30%)

WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

WDAY Workday
$230.93 /

+7.31 (+3.27%)

LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

HIBB Hibbett Sports
$42.14 /

+1.86 (+4.62%)

GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

FL Foot Locker
$41.36 /

+1.35 (+3.37%)

DTIL Precision BioSciences
$9.68 /

+0.21 (+2.22%)

BKE The Buckle
$28.81 /

+1.125 (+4.06%)

AVRO Avrobio
$16.95 /

-0.365 (-2.11%)

WSM Williams-Sonoma
$101.32 /

+4.245 (+4.37%)

WDAY Workday
$230.93 /

+7.31 (+3.27%)

LLY Eli Lilly
$143.46 /

+3.31 (+2.36%)

GSX GSX Techedu
$71.50 /

+3.53 (+5.19%)

FL Foot Locker
$41.36 /

+1.35 (+3.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.